New Radiolabeled Antibody Emerges for Enhanced Diagnosis and Treatment of Solid Tumors

A groundbreaking study published in the April issue of The Journal of Nuclear Medicine reveals a novel radiolabeled antibody with exceptional specificity for the cancer-associated antigen IL13Rα2, ushering in a new frontier in precision oncology imaging and therapy. This innovative antibody, designated KLG-3, selectively targets IL13Rα2-expressing tumor cells while sparing IL13Rα1, a closely related receptor widely distributed in healthy tissues. The unparalleled selectivity of KLG-3 holds significant promise for enhancing molecular imaging fidelity and developing targeted radioimmunotherapy with minimal off-target toxicity.

Interleukin-13 receptor α-2 (IL13Rα2) has long been recognized as an attractive biomarker due to its overexpression in a spectrum of aggressive solid tumors, including glioblastoma, melanoma, and triple-negative breast cancer. Unlike IL13Rα1, which is broadly expressed in non-malignant tissues, IL13Rα2’s restricted presence in normal cells presents an ideal molecular target for tumor-specific interventions. Despite this, no IL13Rα2-directed antibody-based diagnostics or therapeutics have reached clinical use, a gap this research aims to address with compelling preclinical evidence.

The multidisciplinary team, led by Dr. Simone Krebs of the University of Texas MD Anderson Cancer Center and previously at Memorial Sloan Kettering Cancer Center, engineered five novel human antibodies (KLG-1 through KLG-5) uniquely targeting IL13Rα2. Through rigorous in vitro analyses, these antibodies were characterized for affinity, specificity, and cross-reactivity against IL13Rα1, establishing KLG-3 as the lead candidate with superior binding kinetics and selectivity. This specificity is critical to avoiding false-positive signals in diagnostic imaging and minimizing collateral tissue damage during therapy.

In vivo evaluation employed immuno-positron emission tomography (immuno-PET) using zirconium-89 (^89Zr) labeling of KLG-3, applied to glioblastoma xenograft mouse models. High-resolution PET/CT imaging at 144 hours post-injection revealed remarkable tumor uptake with negligible background accumulation in non-target organs. This high tumor-to-normal tissue ratio underscores KLG-3’s potential for accurate tumor delineation and real-time monitoring of tumor burden, a crucial advantage over conventional imaging agents.

To optimize clinical translation, a mass dose titration study was performed, demonstrating that even low antibody doses generated robust signal intensities, enhancing safety profiles by reducing systemic antibody exposure. Complementary ex vivo biodistribution studies further quantified uptake kinetics and clearance pathways, informing dosimetry calculations for a therapeutic counterpart conjugated with lutetium-177 (^177Lu). This theranostic approach integrates precise tumor targeting with cytotoxic radiation delivery.

Extending the applicability of KLG-3 beyond glioblastoma, the antibody was also tested in melanoma models, validating consistent targeting efficiency and favorable pharmacokinetics. These findings open avenues for broad-spectrum applications across multiple IL13Rα2-positive malignancies, underlining the versatility of the antibody platform.

Prospective dosimetry analysis predicted effective tumor radiation dosing at relatively low injected activities of ^177Lu-KLG-3, indicating a promising therapeutic index with reduced side effects. This marks a significant advance toward establishing KLG-3 as a dual-function agent enabling both high-sensitivity tumor imaging and targeted radiotherapy, addressing a critical unmet need in oncology.

Importantly, IL13Rα2 is increasingly implicated in fostering an immunosuppressive tumor microenvironment. By selectively imaging IL13Rα2 expression, KLG-3-based immuno-PET has potential utility in identifying patients with immunosuppressive phenotypes, guiding personalized combinatorial treatment strategies that integrate immune modulation.

The development of KLG-3 reflects a paradigm shift in theranostic design, combining molecular precision with translational feasibility. The extensive collaboration among leading institutions, including Memorial Sloan Kettering Cancer Center, the Tri-Institutional Therapeutics Discovery Institute, and the University of Texas MD Anderson Cancer Center, highlights the multidisciplinary effort to translate these antibodies from bench to bedside.

The study’s implications resonate profoundly across cancer research and clinical practice. By enabling noninvasive, real-time visualization of IL13Rα2-positive tumors with unprecedented specificity and enabling targeted radiotherapy, KLG-3 sets the stage for more effective, less toxic cancer management. Future clinical trials will elucidate its efficacy and safety in human patients, propelling this innovation toward routine clinical adoption.

The authors emphasize that this work not only advances cancer imaging and therapy but also enhances understanding of tumor biology, particularly the immunologic landscape shaped by IL13Rα2. As such, KLG-3 and related antibodies may serve as invaluable tools for cancer diagnosis, treatment planning, and response assessment in personalized medicine.

This landmark research is poised to transform the role of IL13Rα2 from a biomarker of poor prognosis into a pivot for targeted therapeutic intervention, ultimately improving outcomes for patients with challenging malignancies such as glioblastoma and melanoma. The study’s findings represent a crucial step forward in precision oncology’s ongoing revolution.

News Publication Date: April 17, 2025

Web References:
https://doi.org/10.2967/jnumed.124.268762